Hormone Therapy in Breast and Prostate Cancer

ISBN-13: 9780896036734 / Angielski / Twarda / 2002 / 420 str.

Craig V. Jordan; Robert H. Lurie; Barrington J. a. Furr

Opis

In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying targeted hormonal treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide.

Recenzje

From the reviews:

"...takes the reader on a fascinating scientific journey that illustrates how the combination of clinical and basic investigations has realized the first two objectives for both of these prevalent malignancies and, with breast cancer, the promise of being close to prevention." -Foreword by Prof. Elwood Jensen, Professor Emeritus, University of Chicago

"This was a well-written and well-thought-out book on extensive and changing subject matter...the chapter on nonsteroidal antiandrogens is one of the best chapters I've read on the subject. It was very well written and covered the subject thoroughly." -The Annals of Pharmacotherapy

"Hormone Therapy in Breast and Prostate Cancer offers an authoritative state-of-the-art account of the role of hormones in prostate and breast cancer...all of the chapters are extremely useful to both researchers and clinicians. " -Trends in Endocrinology & Metabolism

"I highly recommend this volume for all oncologists who treat these patients and for the laboratory investigators who would like to see how their work is translated to the clinic." -Oncology

"...this is an excellent contemporary review of this field. It will be of interest, in particular, to obviously breast surgeons or urologists with an interest in malignancy and, in particular, those involved in clinical trials." -ANZ J. Surg

"This book, a paperback version of a book originally published in 2002, does a good job of chronicling the history of the major developments in hormone therapy for both breast and prostate cancer. ... I would have recommended it then to any medicinal chemist or pharmacologist that was just starting breast or prostate cancer research ... . can be useful for people looking for a good introduction to hormone therapy ... ." (Ross V. Weatherman, ChemMedChem, Vol. 5, 2010)

"The aim of this book is to trace the origin of endocrine therapy in breast and prostate cancer ... . Overall the book is more detailed than would be expected and is all the better for it. ... This was an interesting book which was much more than the title suggests. It was detailed and the coverage broad giving the reader a wealth of information. The reference lists are very comprehensive ... . Overall this is a very useful text." (Heather M. Wallace, BTS Newsletter, Issue 37, Winter, 2010)

Spis treści

An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer V. Craig Jordan and Barrington J. A. Furr Part I. Preclinical Antiestrogens Antiestrogens and the Cell Cycle Colin K. W. Watts, Owen W. J. Prall, Jason S. Carroll, Nicholas R. C. Wilcken, Eileen M. Rogan, Elizabeth A. Musgrove, and Robert L. Sutherland Drug Resistance to Antiestrogens Ruth M. O'Regan, Anait S. Levenson, Gale M. England, Kathy A. Yao, Henry D. Muenzner, Hiroyuki Takei, and V. Craig Jordan Mechanisms of Liver Carcinogenesis by Antiestrogens David H. Phillips The Effects of Triphenylethylene Antiestrogens on Parameters of Multistage Hepatocarcinogenesis in the Rat Yvonne P. Dragan and Henry C. Pitot Preclinical Studies of Raloxifene and Related Compounds Robin Fuchs-Young. Pure Antiestrogens, Alan E. Wakeling Part II. Antiestrogens: Clinical Tamoxifen for the Treatment of Breast Cancer V. Craig Jordan Clinical Utility of New Antiestrogens Ruth M. O'Regan and William J. Gradishar Breast Cancer Prevention with Antiestrogens Monica Morrow and V. Craig Jordan Part III. Inhibition of Estrogen Synthesis Aromatase Inhibitors Paul E. Goss and Caroline C. Reid Clinical Utility of Aromatase Inhibitors K. Shenton, Mitchell Dowsett, and Michael Dukes LH-RH Agonists for the Treatment of Breast Cancer: Development and Current Status Roger W. Blamey Part IV. Androgen and Androgen Withdrawal Molecular Action of Androgens Shutsung Liao, Junichi Fukuchi, and Yung-Hsi Kao Steroidal Antiandrogens Fritz H. Schröder and Albert Radlmaier Nonsteroidal Antiandrogens Geert J. C. M. Kolvenbag and Barrington J. A. Furr LH-RH Agonist Role in Prostate Cancer Management Amir V. Kaisary Part V. Perspective on Progress Recent Progress in Breast Cancer Research V. Craig Jordan and Barrington J. A. Furr

Blurb

Millions of people are now successfully using hormone antagonists for the treatment of endocrine-dependent cancers. In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying these targeted treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide.
Unique in its synthesis, Hormone Therapy in Breast and Prostate Cancer offers medical and surgical oncologists, urologists, physicians, and clinical pharmacologists a sound basis for understanding targeted treatments of breast and prostate cancers, and provides a well-proven model for developing powerful new cancer therapeutics.